ChromaDex® Enters into Agreement with Beckman Research Institute of City of Hope to Supply pTeroPure™ Pterostilbene for Cancer Research
IRVINE, Calif., July 29, 2013 /PRNewswire/ -- ChromaDex Corporation® (OTCQB: CDXC) ("ChromaDex" or the "Company"), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries, announced today it has entered into a material transfer agreement (MTA) with the Beckman Research Institute of City of Hope ("BRICOH") whereby ChromaDex will provide BRICOH with quantities of its branded pTeroPure™ pterostilbene to be used in preclinical in vitro and mouse model experiments to study its potential therapeutic use for treatment of ovarian, uterine and breast cancer.
According to the Center for Disease Control, over 300,000 women are diagnosed annually with breast, ovarian or uterine cancer. Second only to skin cancer, breast cancer is the most-common cancer among women.1
Commenting on the announcement, Frank Jaksch, ChromaDex founder and CEO, states, "By providing materials to BRICOH for preclinical studies, we will learn more about the potential of pTeroPure's application in cancer. This relationship will complement our ongoing partnership with UC-Irvine, where we are supporting ongoing research on pTeroPure's use for nonmelanoma skin cancer."
Pterostilbene is an antioxidant that is primarily found in blueberries. Studies suggest that pterostilbene exhibits the hallmark characteristics of an effective anticancer agent based on its antineoplastic properties in several common malignancies. In vitro models have shown that pterostilbene inhibits cancer growth through alteration of the cell cycle, induction of apoptosis and inhibition of metastasis. In vivo, pterostilbene inhibits tumorigenesis and metastasis with negligible toxicity. Pterostilbene has also been shown to be effective as an inducer of antioxidant capacity in multiple cancer cell lines that may facilitate its function as an anticarcinogenic compound. Additionally, preliminary studies show that pterostilbene exhibits much greater bioavailability compared with other stilbene compounds; however, the exact pharmacologic mechanism of pterostilbene and its effects in humans are still under investigation.2
1 Source: U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2009 Incidence and Mortality Web-based Report. Atlanta (GA): Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute; 2013. Available at: http://www.cdc.gov/uscs.
2 Source: Denise McCormack MD, David McFadden MD, Journal of Surgical Research, Volume 173, Issue 2 , Pages e53-e61 , April 2012
ABOUT CITY OF HOPE:
City of Hope is a leading research and treatment center for cancer, diabetes and other life-threatening diseases. Designated as a comprehensive cancer center, the highest recognition bestowed by the National Cancer Institute, City of Hope is also a founding member of the National Comprehensive Cancer Network, with research and treatment protocols that advance care throughout the nation. City of Hope's main hospital is located in Duarte, Calif., just northeast of Los Angeles, with clinics in Antelope Valley and South Pasadena. It is ranked as one of "America's Best Hospitals" in cancer by U.S.News & World Report. Founded in 1913, City of Hope is a pioneer in the fields of bone marrow transplantation and genetics. For more information, visit www.cityofhope.org or follow City of Hope on Facebook, Twitter, YouTube or Flickr.
ABOUT BECKMAN RESEARCH INSTITUTE:
Beckman Research Institute of City of Hope is the first of only five Beckman Research Institutes established by funding from the Arnold and Mabel Beckman Foundation. Researchers there are responsible for fundamentally expanding the world's understanding of how biology affects diseases such as cancer, HIV/AIDS and diabetes. Its breakthroughs in the areas of recombinant DNA technology, gene therapy and monoclonal antibodies are testaments to the culture of collaboration that inspires and informs its work.
ChromaDex® is an innovative natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its unique business model which utilizes its wholly-owned synergistic business units, including ingredient technologies, natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services and product regulatory and safety consulting (as Spherix Consulting). The Company provides seamless science-based solutions to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries. Our ingredient technologies unit includes products backed with extensive scientific research and intellectual property. The ingredient portfolio includes pTeroPure® pterostilbene; ProC3G™, a natural black rice containing cyanidine-3-glucoside; PURENERGY™, a caffeine-pTeroPure co-crystal; nutraGac™, a gac fruit powder; curcumin, and Niagen™, its recently launched branding nicotinamide riboside, a novel next-generation B-vitamin. To learn more about ChromaDex please visit www.chromadex.com.
Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the effect of economic conditions both nationally and internationally, ability to protect our intellectual property rights, impact of any litigation or infringement actions brought against us, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, the ability to complete transactions, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.
ChromaDex Investor Contact:
The Del Mar Consulting Group, Inc.
Robert B. Prag, President
Alex Partners, LLC
Scott Wilfong, President
ChromaDex Company Contact:
Laura Carney, Executive Assistant
Statements in this press release have not been evaluated by the Food and Drug Administration. Products or ingredients are not intended to diagnose, treat, cure or prevent any disease.
SOURCE ChromaDex Corporation
More by this Source
ChromaDex® Announces $62 Million Ingredient Agreement with Network Marketing Company 5LINX®
Jan 06, 2014, 08:30 ET
ChromaDex® Updates Research Activity Agreements For Its NIAGEN™ Nicotinamide Riboside
Nov 22, 2013, 08:30 ET
ChromaDex® Reports Results for the Third Quarter 2013
Nov 21, 2013, 17:50 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.